Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Here's Why You Should Retain BD (BDX) to Your Portfolio

BD's (BDX) slew of product launches raises optimism about the stock.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.

Bruker (BRKR) Announces Advanced timsTOF Solutions at US HUPO

Bruker (BRKR) advances CCS-Enabled 4D-Proteomics timsTOF solutions for immunopeptidomes and glycoproteomics at the US HUPO 2024.

GE HealthCare (GEHC) AI Model to Predict Immunotherapy Response

GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.

Thermo Fisher (TMO) Unveils CorEvitas Clinical Registry in GPP

Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.

Cardinal Health (CAH) Hits 52-Week High: What's Driving It?

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.

Reasons to Add The Cooper Companies (COO) to Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Cigna (CI) Unveils Updated Long-Term Growth Targets & Solutions

Cigna (CI) currently estimates long-term average annual adjusted EPS growth within 10-14%. It also came up with new solutions to better manage the rising GLP-1 costs and expand behavioral care.

Should Value Investors Buy DaVita (DVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System

DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.

Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone

Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.

Zacks Investment Ideas feature highlights: Apple, Tesla, HCA Healthcare, DaVita and The Progressive

Apple, Tesla, HCA Healthcare, DaVita and The Progressive have been highlighted in this Investment Ideas article.

Davita (DVA) Shares Gain This Week: Will the Rally Continue?

DaVita (DVA) stock soars as Novo Nordisk's study shows that although weight-loss drug reduces death risk for chronic kidney disease patients, demand for dialysis services will remain.

DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?

A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.

Ethan Feller headshot

Market Leaders Rolling Over: Time to Rotate into Defensive Stocks?

Although the stock market has rallied almost nonstop since the start of the year, cracks are beginning to form

Phibro (PAHC) Appears Well Poised on Launches, Vaccine Sales

Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.

QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis

QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

ResMed (RMD) Debuts the Smallest Full-Face CPAP Mask AirFit F40

ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.

Here's Why You Should Hold on to Neogen (NEOG) Stock Now

Solid progress in long-term growth strategies bodes well for Neogen (NEOG).

DaVita (DVA) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag

Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.